Rigel Pharmaceuticals, Inc.

296 articles with Rigel Pharmaceuticals, Inc.

• Rigel Appoints Dean Schorno as Chief Financial Officer

  5/30/2018

  Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).

• Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.

  5/29/2018

  Rigel Pharmaceuticals, Inc. announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients.

• Rigel Announces First Quarter 2018 Financial Results and Provides Company Update

  5/1/2018

  Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2018.

• TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

  4/30/2018

  Phase 3 clinical program of TAVALISSE™ for the treatment of adults with chronic immune thrombocytopenia.

• Rigel Announces Proposed Public Offering 15,000,000 Of Common Stock

  4/18/2018

  Rigel Pharmaceuticals, Inc. announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering.

• 

  Rigel Website Shows Erroneous Information that Tavalisse Has Been Approved by the FDA

  4/13/2018

  Shares of Rigel Pharmaceuticals shot up about 40 percent during Thursday trading due primarily to an error on the company’s website that claimed its drug candidate Tavalisse had gained approval from the U.S. Food and Drug Administration (FDA).
• 

  Pipeline Concerns: Four Biotechs to Keep Your Eye On

  4/11/2018

  When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.
• 

  Rigel’s Tavalisse Flunks Kidney Disease Trial

  4/3/2018

  Rigel Pharmaceuticals reported a developmental setback for Tavalisse in a mid-stage kidney disease trial. Investors began dumping shares and the stock was down nearly 10 percent.

• Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy

  4/3/2018

  Company to host a conference call today at 8:00AM EDT to Discuss the Study Results

• Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update

  3/6/2018

  Rigel Pharmaceuticals, Inc. reported financial results for the fourth quarter and year end 2017.

• Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America

  3/1/2018

  Fostamatinib disodium is an oral investigational drug candidate designed to inhibit spleen tyrosine kinase, a key signaling component of the body's immune process that leads to platelet destruction in ITP and red blood cell destruction in AIHA.

• Rigel Pharma, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)

  1/30/2018

  Rigel Pharma today announced that on January 15, 2018 and January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 48,000 shares of common stock to three new employees.

• 

  Rigel Pharma Awaits FDA Approval for Tavalisse, Builds Commercial Org for Drug Launch

  1/15/2018

  The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17.
• 

  3 Small-Cap Biotechs That Have Big News on the Way in 2018

  1/8/2018

  More excitement should lie ahead for these small-cap biotechs this year.

• Rigel Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  1/8/2018

  Rigel Pharma today announced that on December 23, 2017 and January 2, 2018 the Compensation Committee of Rigel's Board of Directors approved the grants of inducement stock options to purchase an aggregate of 200,000 shares of common stock to twelve new employees.

• 

  Bay Area Rigel's CFO to Exit, Effective Dec. 31, 2017

  12/15/2017

  Nelson Cabatuan, Rigel's vice president, finance will serve as the company's interim principal accounting officer.

• Rigel Pharma Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  12/11/2017

  Rigel today announced that on December 4, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 60,000 shares of common stock to one new employee.

• Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 ASH Annual Meeting

  12/8/2017

  Rigel Pharma today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be featured in an oral presentation at the 2017 ASH Annual Meeting.

• Rigel Pharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  11/20/2017

  These awards were granted pursuant to the Rigel PharmaInducement Plan, as amended, as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.

• Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

  11/8/2017

  For the third quarter of 2017, Rigel reported a net loss of $17.7M, or $0.14 per basic and diluted share, compared to a net loss of $22.6M, or $0.24 per basic and diluted share, in the same period of 2016.